The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Dry Eye Syndrome Drugs-Global Market Insights and Sales Trends 2025
Synopsis
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment.
In this report, we mainly study the drugs and eye drops for dry eye.
The global Dry Eye Syndrome Drugs market size is expected to reach US$ 6838.6 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Dry Eye Syndrome Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Household Use,, are propelling Dry Eye Syndrome Drugs market. Antibiotic Drops, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hormone Drops segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Dry Eye Syndrome Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Dry Eye Syndrome Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Dry Eye Syndrome Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Dry Eye Syndrome Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Dry Eye Syndrome Drugs covered in this report include Allergan, Novartis, Santen, Takeda, Otsuka, Eyegate Pharma, Can-Fite BioPharma, Bausch and Lomb and Auven Therapeutics (Celtic), etc.
The global Dry Eye Syndrome Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Allergan
Novartis
Santen
Takeda
Otsuka
Eyegate Pharma
Can-Fite BioPharma
Bausch and Lomb
Auven Therapeutics (Celtic)
Bridge Pharma
Cellzome
Global Dry Eye Syndrome Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Dry Eye Syndrome Drugs market, Segment by Type:
Antibiotic Drops
Hormone Drops
Artificial Tears
Global Dry Eye Syndrome Drugs market, by Application
Hospitals
Clinics
Household Use
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Dry Eye Syndrome Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment.
In this report, we mainly study the drugs and eye drops for dry eye.
The global Dry Eye Syndrome Drugs market size is expected to reach US$ 6838.6 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Dry Eye Syndrome Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Household Use,, are propelling Dry Eye Syndrome Drugs market. Antibiotic Drops, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hormone Drops segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Dry Eye Syndrome Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Dry Eye Syndrome Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Dry Eye Syndrome Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Dry Eye Syndrome Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Dry Eye Syndrome Drugs covered in this report include Allergan, Novartis, Santen, Takeda, Otsuka, Eyegate Pharma, Can-Fite BioPharma, Bausch and Lomb and Auven Therapeutics (Celtic), etc.
The global Dry Eye Syndrome Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Allergan
Novartis
Santen
Takeda
Otsuka
Eyegate Pharma
Can-Fite BioPharma
Bausch and Lomb
Auven Therapeutics (Celtic)
Bridge Pharma
Cellzome
Global Dry Eye Syndrome Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Dry Eye Syndrome Drugs market, Segment by Type:
Antibiotic Drops
Hormone Drops
Artificial Tears
Global Dry Eye Syndrome Drugs market, by Application
Hospitals
Clinics
Household Use
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Dry Eye Syndrome Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Dry Eye Syndrome Drugs
1.1 Dry Eye Syndrome Drugs Market Overview
1.1.1 Dry Eye Syndrome Drugs Product Scope
1.1.2 Dry Eye Syndrome Drugs Market Status and Outlook
1.2 Global Dry Eye Syndrome Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Dry Eye Syndrome Drugs Market Size by Region (2018-2029)
1.4 Global Dry Eye Syndrome Drugs Historic Market Size by Region (2018-2023)
1.5 Global Dry Eye Syndrome Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Dry Eye Syndrome Drugs Market Size (2018-2029)
1.6.1 North America Dry Eye Syndrome Drugs Market Size (2018-2029)
1.6.2 Europe Dry Eye Syndrome Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Dry Eye Syndrome Drugs Market Size (2018-2029)
1.6.4 Latin America Dry Eye Syndrome Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Dry Eye Syndrome Drugs Market Size (2018-2029)
2 Dry Eye Syndrome Drugs Market by Type
2.1 Introduction
2.1.1 Antibiotic Drops
2.1.2 Hormone Drops
2.1.3 Artificial Tears
2.2 Global Dry Eye Syndrome Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Dry Eye Syndrome Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Dry Eye Syndrome Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Dry Eye Syndrome Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Dry Eye Syndrome Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Dry Eye Syndrome Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Dry Eye Syndrome Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Dry Eye Syndrome Drugs Revenue Breakdown by Type (2018-2029)
3 Dry Eye Syndrome Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Household Use
3.2 Global Dry Eye Syndrome Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Dry Eye Syndrome Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Dry Eye Syndrome Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Dry Eye Syndrome Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Dry Eye Syndrome Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Dry Eye Syndrome Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Dry Eye Syndrome Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Dry Eye Syndrome Drugs Revenue Breakdown by Application (2018-2029)
4 Dry Eye Syndrome Drugs Competition Analysis by Players
4.1 Global Dry Eye Syndrome Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Dry Eye Syndrome Drugs as of 2022)
4.3 Date of Key Players Enter into Dry Eye Syndrome Drugs Market
4.4 Global Top Players Dry Eye Syndrome Drugs Headquarters and Area Served
4.5 Key Players Dry Eye Syndrome Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Dry Eye Syndrome Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Allergan
5.1.1 Allergan Profile
5.1.2 Allergan Main Business
5.1.3 Allergan Dry Eye Syndrome Drugs Products, Services and Solutions
5.1.4 Allergan Dry Eye Syndrome Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Allergan Recent Developments
5.2 Novartis
5.2.1 Novartis Profile
5.2.2 Novartis Main Business
5.2.3 Novartis Dry Eye Syndrome Drugs Products, Services and Solutions
5.2.4 Novartis Dry Eye Syndrome Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis Recent Developments
5.3 Santen
5.3.1 Santen Profile
5.3.2 Santen Main Business
5.3.3 Santen Dry Eye Syndrome Drugs Products, Services and Solutions
5.3.4 Santen Dry Eye Syndrome Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Takeda Recent Developments
5.4 Takeda
5.4.1 Takeda Profile
5.4.2 Takeda Main Business
5.4.3 Takeda Dry Eye Syndrome Drugs Products, Services and Solutions
5.4.4 Takeda Dry Eye Syndrome Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Takeda Recent Developments
5.5 Otsuka
5.5.1 Otsuka Profile
5.5.2 Otsuka Main Business
5.5.3 Otsuka Dry Eye Syndrome Drugs Products, Services and Solutions
5.5.4 Otsuka Dry Eye Syndrome Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Otsuka Recent Developments
5.6 Eyegate Pharma
5.6.1 Eyegate Pharma Profile
5.6.2 Eyegate Pharma Main Business
5.6.3 Eyegate Pharma Dry Eye Syndrome Drugs Products, Services and Solutions
5.6.4 Eyegate Pharma Dry Eye Syndrome Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Eyegate Pharma Recent Developments
5.7 Can-Fite BioPharma
5.7.1 Can-Fite BioPharma Profile
5.7.2 Can-Fite BioPharma Main Business
5.7.3 Can-Fite BioPharma Dry Eye Syndrome Drugs Products, Services and Solutions
5.7.4 Can-Fite BioPharma Dry Eye Syndrome Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Can-Fite BioPharma Recent Developments
5.8 Bausch and Lomb
5.8.1 Bausch and Lomb Profile
5.8.2 Bausch and Lomb Main Business
5.8.3 Bausch and Lomb Dry Eye Syndrome Drugs Products, Services and Solutions
5.8.4 Bausch and Lomb Dry Eye Syndrome Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Bausch and Lomb Recent Developments
5.9 Auven Therapeutics (Celtic)
5.9.1 Auven Therapeutics (Celtic) Profile
5.9.2 Auven Therapeutics (Celtic) Main Business
5.9.3 Auven Therapeutics (Celtic) Dry Eye Syndrome Drugs Products, Services and Solutions
5.9.4 Auven Therapeutics (Celtic) Dry Eye Syndrome Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Auven Therapeutics (Celtic) Recent Developments
5.10 Bridge Pharma
5.10.1 Bridge Pharma Profile
5.10.2 Bridge Pharma Main Business
5.10.3 Bridge Pharma Dry Eye Syndrome Drugs Products, Services and Solutions
5.10.4 Bridge Pharma Dry Eye Syndrome Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Bridge Pharma Recent Developments
5.11 Cellzome
5.11.1 Cellzome Profile
5.11.2 Cellzome Main Business
5.11.3 Cellzome Dry Eye Syndrome Drugs Products, Services and Solutions
5.11.4 Cellzome Dry Eye Syndrome Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Cellzome Recent Developments
6 North America
6.1 North America Dry Eye Syndrome Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Dry Eye Syndrome Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Dry Eye Syndrome Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Dry Eye Syndrome Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Dry Eye Syndrome Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Dry Eye Syndrome Drugs Market Dynamics
11.1 Dry Eye Syndrome Drugs Industry Trends
11.2 Dry Eye Syndrome Drugs Market Drivers
11.3 Dry Eye Syndrome Drugs Market Challenges
11.4 Dry Eye Syndrome Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
